Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Lancet
J E
JE
List
A F
AF
Moscinski
L C
LC
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics* / Q000648:ultrastructure; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D007951:Leukemia, Myeloid / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D012074:Remission Induction; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide